

Közlemények jegyzéke

Ph.D. fokozat megszerzés előtt:

1. Szánya JE, **Szakály P**, Magyarlaki T, Balogh Z, Nagy J, Kalmár Nagy K: Predictive morphological findings in „Zero-hour” biopsies of Renal Allografts. *Acta Chirurgica* 36:(1-4), 346-8, 1997

IF: 0

Független idéző: 19

1. Woestenburg AT, Verpooten GA, Ysebaert DK, Van Marck EA, Verbeelen D, Bosmans JL: Fibrous Intimal Thickening at Implantation Aversely Affects Long-Term Kidney Allograft Function. *Transplantation*, 2009; 87, 72-8
2. Woestenburg A, Sennesael J, Bosmans JL, Verbeelen D: Vasculopathy in the kidney allograft at time of transplantation: Impact on later function of the graft. *Transplantation*, 2008; 85, 10-8
3. Kiser RL, Thomas DB, Andreoni K, Klemmer PJ: Preexisting crescentic glomerulonephritis in the renal allograft. *American Journal of Kidney Diseases*, 2003; 42, 23
4. Degawa H, Matsuno N, Iwamoto H, Hama K, Nakamura Y, Narumi Y, Kikuchi K, Uchiyama M, Kozaki K, Nagao T: Primary nonfunctioning grafts in cadaveric kidney transplantation. *Transplantation Proceedings*, 2000; 32, 1903-1904
5. Muruve NA, Steinbecker KM, Luger AM: Are wedge biopsies of cadaveric kidneys obtained at procurement reliable? *Transplantation*, 2000; 69, 2384-2388
6. Bosmans JL, Woestenburg A, Ysebaert DK, Chapelle T, Helbert MJ, Corthouts R, Jurgens A, Van Daele A, Van Marck EA, De Broe ME, Verpooten GA: Fibrous intimal thickening at implantation as a risk factor for the outcome of cadaveric renal allografts. *Transplantation*, 2000; 69, 2388-2394
7. Malaise J, Cosyns JP, Lallier M, Meyr M, Mourad M: Baseline biopsy for the quality assessment of kidney graft. *Current Opinion In Organ Transplantation*, 1999; 4, 139
8. Legendre C, Anglicheau D, Flamant M, Cotté I, Thervet E, Martinez F, Noel LH, Janin A, Droz D: Biopsies systematiques ou non? *Actualites Nephrologiques Jean Hamburger*, 2002; 281-295
9. Guimaraes-Souza N, Dalboni M, Batista M, Canziani M, Camara N, Pacheco-Silva A, Medina-Pestana J, Cendoroglo M: Dialysis adequacy after deceased donor transplantation. *Transplantation Proceedings*, 2009; 41, 1210-1213
10. Jain M, Gupta RK, Kumar A, Mandhani A, Dharma RK: Significance of „zero-hour” graft biopsy in live related renal allograft recipients. *Indian Journal of Nephrology*, 2003; 13, 98-103
11. Sen S, Özkahya M, Hoscokun C, Basdemir G: Morphological findings of zero hour needle biopsies and their influence on early graft function. *Office Journal of the Turkish Nephrology*, 2000; 1, 30-36

12. Sen S, Basdemir G: The importance of histological findings in zero hour needle biopsies of renal transplants. *Tip Dergisi*, 2000; 39, 11-17
 13. Freeland SJ, Mishkin F, Shoskes DA: Effective renal plasma flow calculated from a single blood sample following technetium-99m mercaptoacetyl triglycine renal scan predict delayed graft function in renal transplant. *Techniques in Urology*, 2001; 7(4), 281-284
 14. Tsuchimoto A, Masutani K, Haruyama N, Nagata M, Noguchi H, Okabe Y, Kitada H, Tanaka M, Tsuruya K, Kitazono T: Renal interstitial fibrosis in 0-hour biopsy as a predictor of posttransplant anaemia. *American Journal of nephrology*, Volume 38, Issue 4, Pages 267-74, Published: October 2013
 15. Kasiske BK, Stewart DE, Bista BR, Salkowski N, Snyder JJ, Israni AK, Crary GS, Rosendale JD, Matas A, Delmonico FL: The role of procurement biopsies in acceptance decisions for kidneys retrieved for transplant. *Clinical Journal of the American Society of Nephrology* 2014; 9(3): 562-71
 16. Asd
 17. Asd
 18. Sad
 19. asd
2. **Szakály P**, Magyarlaki T, Kalmár Nagy K: Null-biopszia klinikai értéke vesetranszplantációban. *Magyar Sebészet* 54:(1), 18-22, 2001.
IF:0
Független idéző: 1
 1. Lubuska L, Bachleda P, Tichy T, Lubusky M, Utikal P, Hrabalova M, Chudacek J, Janout V, Lubuska L, Bachleda P, Tichy T, Lubusky M, Utikal M, Hrabalova M, Chudacek J, Janout V: assessment of renal graft function depending on pre-transplant morphology. *Biomed Pap Med Fac Univ Palacky Olomouc* 2006; 150, 171-7
 3. **Szakály P**, Kalmár Nagy K, Kelemen D, Cseke L, Tavakoli A, Kassai M, Papp A, Sajjadi SG, Horváth ÖP: 300 vesetranszplantáció eredményei. *Magyar Sebészet*, 56, 193-8, 2003
 4. Kalmár Nagy K, Baumann J, **Szakály P**, Györi Molnár I, Wittmann I, Lodge P, Horváth ÖP: Kombinált hasnyálmirigy – veseátültetés – veseelégtelenséggel szövődött 1. típusú diabetes mellitus kezelésének alternatív módja. *Orvosi Hetilap*, 145:(24), 1259-64, 2004
IF: 0
Független idéző: 2
 1. Kóbori L, Langer R: A hasi szövetek transzplantációja. *Orvosképzés* Volume: 83, Issue: 3 Pages: 255-260 Published: 2008
 2. Földes K, Piros L, Toronyi E, Wagner L, Chmel R, Török Sz, Nagy K, Ghimessy A, Brinzanek D, Pöcze B, Langer RM, Gerő L. Examination of carbohydrate metabolism parameters after simultaneous pancreas-kidney transplantation. *Transplant Proc.* 2013; 45(10): 3698-702

5. Sulowicz W, Bachleda P, Rydzewski A, Rutkowski B, **Szakály P**, Asztalos L, Samlik J, Lackova E, Ksiazek A, Studenik P, Mysliwiec M, Hruba Z, Navrátil P, Gumprecht J: Discontinuation of mycophenolate mofetil from a tacrolimus-based triple regimen 2 months after renal transplantation: a comparative randomized multicentre study. *Transplant International*, 20:(3), 230-7, 2007

IF: 2,300

Független idéző: 1

1. Vanhove T, Kuypers D, Claes KJ, Evenpoel P, Meijers B, Naesens M, Vanrenterghem Y, Cornelis T, Bammens B: Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. *Transplant International*, Volume: 26, Issue: 8, Pages: 813-21. Published: August 2013
6. Tedesco-Silva H, **Szakaly P**, Shoker A, Sommerer C, Yoshimura N, Schena FP, Cremer M, Hmissi A, Mayer H, Lang P: FTY720 versus MMF in *de novo* renal transplantation: 6-month results of a double-blind study. *Transplantation* 84:(7), 885-92, 2007

IF: 3,641

Független idéző: 50

1. Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA: Early tolerability and safety of fingolimod in clinical practice. *Journal Of The Neurological Sciences* Volume: 323 Issue: 1-2 Pages: 167-172 Published: 15 December 2012
2. Ontaneda D, Di Capula D: Benefits versus risks of latest therapies in multiple sclerosis: a perspective review. *Therapeutic Advances In Drug Safety* Volume: 3 Issue: 6 Pages: 291-303 Published: December 2012
3. Cervera C: Infections and fingolimod. *Revista De Neurologia* Volume: 55 Issue: 4 Pages: 227-237 Published: AUG 16 2012
4. Giannoudaki E, Swan DJ, Kirby JA, Ali S: Sphingosine-1-phosphate signaling as a therapeutic target. *Cell Health And Cytoskeleton* Volume: 4 Pages 63-72 DOI: <http://dx.doi.org/CHC.S34014> Published: July 2012
5. Stradner MH, Angerer H, Ortner T, Fuerst FC, Setznagel D, Kremser ML, Hermann J, Graninger WB: The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage. *BMC Musculoskeletal Disorders* Volume: 12 Article Number: 279 DOI: 10.1186/1471-2474-12-279 Published: 12 Dec 2011
6. Marcus A, Eshhar Z: Tumor-specific allogeneic cells for cancer therapy. *Expert Opinion On Biological Therapy* Volume: 11 Issue: 12 Pages: 1551-1554 DOI: 10.1517/14712598.2011.628934 Published: Dec 2011
7. Hoitsma AJ, Woodle ES, Abramowicz D, Proot P, Vanrenterghem Y: FTY720 combined with tacrolimus in *de novo* renal transplantation: 1-year, multicenter, open-label randomized study FTY720 Phase II Transplant Study G *Nephrology*

Dialysis Transplantation Volume: 26 Issue: 11 Pages: 3802-3805 DOI: 10.1093/ndt/gfr503 Published: Nov 2011

8. Blaho VA, Hla T: Regulation of Mammalian Physiology, Development, and Disease by the Sphingosine 1-Phosphate and Lysophosphatidic Acid Receptors. *Chemical Reviews* Volume: 111 Issue: 10 Pages: 6299-6320 DOI: 10.1021/cr200273u Published: Oct 2011
9. Pchejetski D, Boehler T, Stebbing J, Waxman J: Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. *Nature Reviews Urology* Volume: 8 Issue: 10 Pages: 569-578 DOI: 10.1038/nrrol.2011.117 Published: Oct 2011
10. Medina-Pestana JO, Galante NZ, Silva Jr HT, Harada KM, Garcia VD, Abbud-Filho M, de Holnanda Campos H, Emil Sabbage: Kidney transplantation in Brazil and its geographic disparity. *J Bras Nefrol* Volume: 33 Issue: 4 Pages: 472-484 Published: Oct/Nov/Dec 2011.
11. Müller HC, Hocke AC, Hellwig K, Gutbier B, Peters H, Schonrock SM, Tschering T, Schmiedl A, Hippenstiel S, N'Guessan PD, Rosseau S, Suttorp N, Witzenrath M: The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. *Pulmonary Pharmacology & Therapeutics* Volume: 24 Issue: 4 Pages: 377-385 DOI: 10.1016/j.pupt.2011.01.017 Published: Aug 2011
12. Marcus A, Waks T, Eshhar Z: Redirected tumor-specific allogeneic T cells for universal treatment of cancer. *Blood* Volume: 118 Issue: 4 Pages: 975-983 DOI: 10.1182/blood-2011-02-334284 Published: 28 Jul 2011
13. Silva Jr, HT, Felipe CR, Abbud M, Garcia V, Medina-Pestana JO: The Emerging Role of Brazil in Clinical Trial Conduct for Transplantation. *American Journal Of Transplantation* Volume: 11 Issue: 7 Pages: 1368-1375 DOI: 10.1111/j.1600-6143.2011.03564.x Published: Jul 2011
14. Ettenger R, Schmouder R, Kovarik JM, Bastien MC, Hoyer PF: Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants. *Pediatric Transplantation* Volume: 15 Issue: 4 Pages: 406-413 DOI: 10.1111/j.1399-3046.2011.01498.x Published: Jun 2011
15. Iwasaki T, Tsunemi S, Kitano S, Kanda C, Sekiguchi M, Kitano M, Sano H: Role of shingosine 1-phosphate signaling for the pathogenesis of autoimmune diseases. *Infalmmation And Regeneration* Volume: 31 Issue: 2 Pages: 175-183 Published: 2 Mar 2011
16. Miller CE, Umhauer MA: Emerging Oral Therapies for Multiple Sclerosis. *Journal Of Neuroscience Nursing* Volume: 43 Issue: 1 Pages: 3-14 DOI: 10.1097/JNN.0b013e31820297a9 Published: Feb 2011
17. Chiang E, Wang T, Garcia JGN: Acute Lung Injury: The Injured Lung Endothelium, Therapeutic Strategies for Barrier Protection, and Vascular Biomarkers. *Textbook Of Pulmonary Vascular Disease* Pages: 197-222 DOI: 10.1007/978-0-387-87429-6_12 Published: 2011
18. White CA, Siegal D, Akbari A, Knoll GA: Use of Kidney Function End Points in Kidney Transplant Trials: A Systematic Review. *American Journal Of Kidney Diseases* Volume: 56 Issue: 6 Pages: 1140-1157 DOI: 10.1053/j.ajkd.2010.08.015 Published: Dec 2010

19. Shea BS, Brooks SF, Fontaine BA, Chun J, Luster Ad, Tager AM: Prolonged Exposure to Sphingosine 1-Phosphate Receptor-1 Agonists Exacerbates Vascular Leak, Fibrosis, and Mortality after Lung Injury. *American Journal Of Respiratory Cell And Molecular Biology* Volume: 43 Issue: 6 Pages: 662-673 DOI: 10.1165/rcmb.2009-0345OC Published: Dec 2010
20. Li Q, Li F: Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats. *Immunopharmacology And Immunotoxicology* Volume: 32 Issue: 4 Pages: 680-687 DOI: 10.3109/08923971003674433 Published: Dec 2010
21. Foucher Y, Daguin P, Akl A, Kessler M, Ladrière M, Legendre C, Kreis H, Rostaing L, Kamar N, Mourad G, Garrigue V, Bayle F, De Lingny BH, Büchler M, Meier C, Daures JP, Soullillou JP, Giral M: A clinical scoring system highly predictive of long-term kidney graft survival. *Kidney International* Volume: 78 Issue: 12 Pages: 1288-1294 DOI: 10.1038/ki.2010.232 Published: Dec 2010
22. Lang PA, Merkler D, Funkner P, Shaabani N, Meryk A, Krings C, Barthuber C, Rechner M, Brück W, Häussinger D, Ohashi PS, Lang KS: Oxidized ATP inhibits T-cell-mediated autoimmunity. *EUROPEAN Journal Of Immunology* Volume: 40 Issue: 9 Pages: 2401-2408 DOI: 10.1002/eji.200939838 Published: Sep 2010
23. Schwarz A, Korporal M, Hosch W, Max R, Wildemann B: Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. *Neurology* Volume: 74 Issue: 24 Pages: 2022-2024 Published: Jun 15 2010
24. Sensken S-C, Graeler MH.: Down- regulation of S1P(1) Receptor Surface Expression by Protein Kinase C Inhibition. *Journal Of Biological Chemistry* Volume: 285 Issue: 9 Pages: 6298-6307 DOI: 10.1074/jbc.M109.049692 Published: Feb 26 2010
25. Camp SM, Bittman R, Chiang ET, Moreno-Vinasco L, Mirzapoiiazova T, Sammani S, Lu X, Sun C, Harbeck M, Roe M, Natarajan V, Garcia JGN, Dudek SM: Synthetic Analogs of FTY720 [2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] Differentially Regulate Pulmonary Vascular Permeability in Vivo and in Vitro *Journal Of Pharmacology And Experimental Therapeutics* Volume: 331 Issue: 1 Pages: 54-64 DOI: 10.1124/jpet.109.153544 Published: Oct 2009
26. Kumar A, Saba JD: Lyase to live by: Sphingosine phosphate lyase as a therapeutic target. *Expert Opinion On Therapeutic Targets* Volume: 13 Issue: 8 Pages: 1013-1025 DOI: 10.1517/14728220903039722 Published: Aug 2009
27. Zhou PJ, Wang H, Shi GH, Wang XH, Shen ZJ, Xu D: Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro. *Clinical And Experimental Immunology* Volume: 157 Issue: 1 Pages: 40-47 DOI: 10.1111/j.1365-2249.2009.03942.x Published: Jul 2009
28. Villarroel MC, Hidalgo M, Jimeno A: Mycophenolate mofetil: An update. *Drugs Of Today* Volume: 45 Issue: 7 Pages: 521-532 DOI: 0.1358/dot.2009.45.7.1384878 Published: Jul 2009
29. Ishii M, Egen JG, Klauschen F, Meier-Schnellersheim M, Saeki Y, Vacher J, Proia RL, Germain RN: Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. *Nature* Volume: 458 Issue: 7237 Pages: 524-8 DOI: 10.1038/nature07713 Published: 26 Mar 2009

30. Cooper S, Giles FJ, Savona MR: Overcoming resistance in chronic myelogenous leukemia. *Leukemia & Lymphoma* Volume: 50 Issue: 11 Pages: 1785-1793 DOI: 10.3109/10428190903267559 Published: 2009
31. Wolfson RK, Lang G, Jacobson J, Garcia JGN: Therapeutic strategies to limit lung endothelial cell permeability. *Book Of The Pulmonary Endothelium, Function In Health And Disease*. Published: 2009 Könyvfejezet
32. Parrill AL, Baker DL: Autotaxin Inhibition: Challenges and Progress Toward Novel Anti-Cancer Agents. *Anti-Cancer Agents In Medicinal Chemistry* Volume: 8 Issue: 8 Pages: 917-923 Published: Dec 2008
33. Lynch KR, Macdonald TL: Sphingosine 1-phosphate chemical biology. *Biochimica Et Biophysica Acta-Molecular And Cell Biology Of Lipids* Volume: 1781 Issue: 9 Pages: 508-512 DOI: 10.1016/j.bbali.2008.06.006 Published: Sep 2008
34. Rosen H, Gonzalez-Cabrera P, Marsolais D, Cahalan S, Don AS, Sanna MG: Modulating tone: the overture of S1P receptor immunotherapeutics. *Immunological Reviews* Volume: 223 Pages: 221-235 DOI: 10.1111/j.1600-065X.2008.00645.x Published: Jun 2008
35. Yuan W, Lu X-H, Zhang Y-Q, Yu H-H, Gong Y-B: Cyclosporin A effects on expressions of tumor necrosis factor-related apoptosis-including ligand and death receptor 4 in rat corneal allografts during acute rejection phase. *Journal Of Clinical Rehabilitative Tissue Engineering Research* Volume: 12 Pages: 3453-3456 Published: 29 APR 2008
36. Keller CD: Profibrotische Effekte von Sphingosin-1-Phosphat- Rezeptoragonisten in primären humanen dermalen Fibroblasten. Dissertation, Berlin, Juni 2008
37. Alshaker H, Sauer L, Monteil D, Ottaviani S, Böhler T, Pchejetski D: Therapeutic potential of Targeting SK1 in Human Cancers. *Advances in Cancer Research* Volume: 117 Pages: 143-200 Published: 2013
38. Koscielny A, Engel D, Maurer J, Wehner S, Kurts C, Kalff JC: The role of lymphoid tissue in the attenuation of postoperative ileus. *American Journal of Physiology - Gastrointestinal and Liver Physiology*, Volume 304, Issue 4, Pages 401-12, 15 February 2013
39. Drognitz A, Neeff H, Pisarski P, Hopt UT: Was gibt es Neues in der Transplantationschirurgie? In: Was gibt es Neues in der Chirurgie? *comed Medizin*, 2008. p233 ISBN: 978-3-609-76979-0
40. Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Bohler T, Pchejetski D: Therapeutic potential of targeting SK1 in human cancers. Role of sphingolipids in cancer development and therapy. Book series: *Advances in cancer research*. Volume: 117, Pages: 143-200 DOI: 10.1016/B978-0-12-394274-6.00006-6. Published: 2013
41. Pereira FV, Arruda DC, Figueiredo CR, Massaoka MH, Matsuo AL, Bueno V, Rodrigues EG: FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. *Clinics*. Volume: 68 Issue: 7 Pages: 1018-27 DOI: 10.6061/clinics/2013(07)21 Published: 2013
42. Khattar M, Deng R, Kahan BD, Shroder PM, Phan T, Rutzky LP, Stepkowski SM: Novel Sphingosine-1-Phosphate receptor modulator KRP203 combined with

locally delivered regulatory T cells induces permanent acceptance of pancreatic islet allografts: Transplantation. Volume: 95 Issue: 7 Pages: 919-27 Published: 2013

43. DSD
44. SAdas
45. Asd
46. AS
47. As
48. AS
49. SAD
50. SAD

7. **Szakály P**, Kiss P, Magyarlaci T, Tamás A, Lubics A, Rácz B, Reglódi D: Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia. *Journal of Molecular Neuroscience* 36:(1-3) 89-96, 2008

IF: 2,061

Független idéző: 9

1. Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V. Pituitary adenylate cyclase activating polypeptide ameliorates cisplatin-induced acute kidney injury. *Peptides* 2010; 31: 592-602.
2. Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V. Pituitary adenylate cyclase activating polypeptide prevents cisplatin-induced renal failure. *J Mol Neurosci* 2011; 43: 58-66.
3. Khan AM, Li M, Brant E, Maderdrut JL, Majid DSA, Simon EE, Batuman V. Renoprotection with pituitary adenylate cyclase activating polypeptide in cyclosporine A-induced nephrotoxicity. *J Invest Med* 2011; 59: 793-802.
4. Khan AM, Li M, Abdounour-Nakhoul S, Maderdrut JL, Simon EE, Batuman V. Delayed administration of pituitary adenylate cyclase activating polypeptide 38 ameliorates renal ischemia/reperfusion injury in mice by modulating Toll-like receptors. *Peptides* 2012; 38: 395-403.
5. Eiden Lee: PACAP and cellular protection by members of the VIP/Secretin family with an emphasis on pituitary adenylate cyclase-activating polypeptide (PACAP). In Nyhag FJ: *Neuropeptides in Neuroprotection and Neuroregeneration*. IBSN: 978-1-4398-3062-8, 2012. Könyvfejezet
6. Herrera VLM, Pasion KA, Moran AM, Ruiz-Opazo N: Worse renal disease in postmenopausal F2[Dahl SxR]-intercross rats: detection of novel QTLs affecting hypertensive kidney disease. *PLoS ONE*, 8(2), Article number 56096, 5 February 2013
7. ASD
8. ASD
9. ASD

8. **Szakály P**, Kalmár Nagy K, Wittmann I: Szoliter hasnyálmirigy átültetés első esete Magyarországon. *Orvosi Hetilap*, 149:(9) 387-91, 2008

Ph.D. fokozat megszerzése után:

9. **Szakály P:** A „null-biopszia” klinikai értéke. Magyar Sebészet, 62:(4), 188-198, 2009
 10. Fekecs T, Kádár Z, Battyáni Z, Kalmár-Nagy K, **Szakály P**, Horváth OP, Wéber G, Ferencz A.: Incidence of nonmelanoma skin cancer after human organ transplantation: single-center experience in Hungary. Transplantation Proceedings 42:(6), 2333-5, 2010
IF: 0,993
Független idéző: 22
1. Mudigonda T, Levender MM, O'Neill JL, West CE, Pearce DJ, Feldman SR: Incidence, risk factors, and preventive management of skin cancers in organ transplant recipients: A review of single- and multicenter retrospective studies from 2006 to 2010. Dermatologic Surgery, Volume 39, Issue 3 PART 1, 345-64, March 2013
 2. Borges-Costa J, Vasconcelos JP, Travassos Ar, Guerra J, Santana A, Weigert A, Sacramento Marques M: Skin cancer in kidney transplant recipients: incidence and association with clinical and demographic factors. Acta Medica Portuguesa, Volume: 26, Issue: 2, Pages 123-6, Published: Mar-Apr 2013
 3. Sulowicz J, Wojas-Pelc A, Ignacak E, Janda K, Betkowska-Prokop A, Kuzniewski M, Soluwicz W: Location of nonmelanoma skin cancer in patients after kidney Transplantation. Polskie Archiwum Medycyny Wewnietrznej-Polish Archives of Internal Medicine 2014; 124(5): 233-8
 4. Tepeoglu M, Ayva S, Atilgan AO, Tuncz MZ, Ozdemir BH, Moray G, Yildirim S, Arslan G, Haberal M: Nonmelanoma skin cancer after kidney transplant. Experimental and Clinical Transplantation 2014; 12(3): 233-7
 5. DA
 6. AD
 7. DF
 8. ASD
 9. ASD
 10. A
 11. ADS
 12. DS
 13. AD
 14. DFAS
 15. DF
 16. SDF
 17. DSF
 18. SD
 19. SD
 20. DSF
 21. DSF
 22. DF

11. Fekecs T, Kádár Z, Battyáni Z, Kalmár-Nagy K, **Szakály P**, Horváth OP, Wéber G, Ferencz A: Changes in oxidative stress in patients screened for skin cancer after solid-organ transplantation. *Transplantation Proceedings* 42:(6), 2336-8, 2010

IF: 0,993

Független idéző: 5

1. Cai F, Dupertuis YM, Pichard C: Role of polyunsaturated fatty acids and lipid peroxidation on colorectal cancer risk and treatments. *Current Opinion In Clinical Nutrition And Metabolic Care* Volume: 15 Issue: 2 Pages: 99-106 Published: March 2012
2. Rietz A, Zänker KS: Skin protecting molecules - Quo vadis? Fromchemoprevention to culturally influenced aesthetic dermatology. *Aktuelle Dermatologie* Volume: 38 Issue: 5 Pages: 167-172 Published: 2012
3. Nafar M, Sahraei Z, Salamzadeh J, Samavat S, Vaziri ND: Oxidative stress in kidney transplantation causes, consequences, and potential treatment. *Iranian Journal Of Kidney Diseases* Volume: 5 Issue: 6 Pages: 357-372 Published: Nov 2011
4. Bergler-Czop B, Brzezinska-Wcislo L, Krauze E, Trzmiel D: Squamous cell carcinoma and metastases of malignant melanoma during immunosuppression in a patient suffering from pemphigus foliaceus - Case report. *Postepy Dermatologii* Volume: 28 Issue: 4 Pages: 317-322 Published: 2011
5. AD

12. Fekecs T, Kádár Z, Battyáni Z, Kalmár Nagy K, **Szakály P**, Wéber G, Horváth OP, Ferencz A: A szervtranszplantációt követő non-melanoma bőrtumorok klinikai vizsgálata. *Magyar Sebészet* 63:(2), 84-90, 2010

Független idéző: 1

1. Cai F,

13. Horvath G, Mark L, Brubel R, **Szakaly P**, Racz B, Kiss P, Tamas A, Helyes Z, Lubics A, Hashimoto H, Baba A, Shintani S, Furjes G, Nemeth J, Reglodi D: Mice deficient in pituitary adenylate cyclase activating polypeptide display increased sensitivity to renal oxidative stress in vitro. *Neurosci Letters*, 469:(1)70-4, 2010

IF: 2,055

Független idéző: 5

1. Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V. Pituitary adenylate cyclase activating polypeptide prevents cisplatin-induced renal failure. *J Mol Neurosci* 2011; 43: 58-66.
2. Moody TW, Ito T, Osefo N, Jensen RT. VIP and PACAP: recent insights -into their functions/roles in physiology and disease from molecular and genetic studies. *Curr Opin Endocrinol Diabetes Obes* 2011; 18: 61-67.

3. Mester L: Új terápiás lehetőségek vizsgálata ischemia okozta retinakárosodásban állatkísérletes és sejtenyészeten végzett vizsgálatok segítségével. PhD thesis 2010
4. SA
5. SAD

14. Horvath G, Racz B, **Szakaly P**, Kiss P, Laszlo E, Hau L, Tamas A Helyes Z, Lubics A, Hashimoto H, Baba A, and Reglodi D: Mice Deficient in Neuropeptide PACAP Demonstrate Increased Sensitivity to In Vitro Kidney Hypoxia. Transplantation Proceedings 42:(6), 2293-5, 2010

IF: 0,993

Független idéző: 6

1. Seaborn T, Masmoudi O, Fournier A, Vaudry H, Vaudry D. Protective effects of pituitary adenylate cyclase activating polypeptide (PACAP) against apoptosis. *Curr Pharm Des* 2011; 17: 204-214.
2. Vacas E, Bajo AM, Schally AV, Sanchez-Chapado M, Prieto JC, Carmena MJ. Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells. *Peptides* 2012; 38: 275-281.
3. Eiden LE: PACAP and cellular Protection: Cellular Protection by Members of the VIP/Secretin Family with an Emphasis on Pituitary Adenylate Cyclase Activating Polypeptide (PACAP). In: *Neuropeptides in Neuroprotection and Neurogeneration*. ISBN: 978-1-4398-3062-8. 2012. Könyvfejezet
4. Vacas OE: Receptores y vías de senalización de VIP como dianas terapéuticas en el cáncer renal. Dissertáció 2012.
5. Sa
6. sad

15. Horvath G, Racz B, Reglodi D, Kovacs K, Kiss P, Gallyas F Jr, Bogнар Z, Szabo A, Magyarlaki T, Laszlo E, Lubics A, Tamas A, Toth G, **Szakaly P**: Effects of PACAP on Mitochondrial Apoptotic Pathways and Cytokine Expression in Rats Subjected to Renal Ischaemia/Reperfusion. *Journal of Molecular Neuroscience* 42:(3),411-8, 2010

IF: 2,922

Független idéző: 12

1. Gao J, Zhang D, Yang X, Zhang Y, Li P, Su X. Lysophosphatidic acid and lovastatin might protect kidney in renal I/R injury by downregulating MCP-1 in rat. *Renal Failure* 2011; 33: 805-810.
2. Kambe Y, Miyata A. Role of mitochondrial activation in PACAP dependent neurite outgrowth. *J Mol Neurosci* 2012; 48: 550-557.
3. Huang S, Li M, Zhang H, He Q, Jiang S, Jim Q: Protection of Danshen on tubular cell induced by renal ischemia reperfusion injury in rats. *China Modern Medicine*, 2010; 11(17): 805-10
4. Eiden LE: PACAP and cellular Protection: Cellular Protection by Members of the VIP/Secretin Family with an Emphasis on Pituitary Adenylate Cyclase Activating

Polypeptide (PACAP). In: Neuropeptides in Neuroprotection and Neurogeneration. ISBN: 978-1-4398-3062-8

5. Cafe-Mendes CC, Ferro ES, Britto LRG, Martins-de-Souza D: Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson's Disease and Schizophrenia CURRENT TOPICS IN MEDICINAL CHEMISTRY (ISSN: 1568-0266) 14: (3) pp. 369-381. (2014)
6. SDA
7. Asd
8. Asd
9. Asd
10. Asd
11. Sad
12. As

16. **Szakaly P**, Horvath G, Kiss P, Laszlo E, Farkas J, Furjes G, Nemeth J, Reglodi D: Changes in Pituitary Adenylate Cyclase-Activating Polypeptide Following Renal Ischemia-Reperfusion in Rats. Transplantation Proceedings 42:(6), 2283-6, 2010

IF: 0,993

Független idéző: 6

1. Khan A-M, Li M, Abdulnour-Nakhoul S, Maderdrut JL, Simon EE, Batuman V: Delayed administration of pituitary adenylate cyclase-activating polypeptide 38 ameliorates renal ischaemia/reperfusion injury in mice by modulating Toll-like receptors. Peptides Volume: 38 Issue: 2 Pages: 395-403 Published: Dec 2012
2. Eiden LE: PACAP and cellular Protection: Cellular Protection by Members of the VIP/Secretin Family with an Emphasis on Pituitary Adenylate Cyclase Activating Polypeptide (PACAP). In: Neuropeptides in Neuroprotection and Neurogeneration. ISBN: 978-1-4398-3062-8, 2012. Könyvfejezet
3. Acton A: Phosphorus-oxygen Lyases: Advances in Research and Application, 2011. Könyvfejezet
4. Ma BQ, Zhang M, Ba L: Plasma pituitary adenylate cyclase-activating polypeptide concentrations and mortality after acute spontaneous basal ganglia hemorrhage. Clinica Chimica Acta 2015; 439: 102-6
5. ASD
6. SAD

17. Brubel R, Horvath G, Reglodi D, Lubics A, Tamas A, Kiss P, Laszlo E, Nemeth J, Mark L, **Szakaly P**: Presence of pituitary adenylate activating polypeptide and its type I receptor in the rat. Transplantation Proceedings 43(4),1297-9, 2011

IF: 1,005

Független idéző: 5

1. Glorie LLF, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N, D'Haese PC, De Meester I, De Beuf A. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol – Renal Physiol

2012; 303: F681-688.

2. Herrera VLM, Pasion KA, Moran AM, Ruiz-Opazo N: Worse renal disease in postmenopausal F2[Dahl SxR]-intercross rats: detection of novel QTLs affecting hypertensive kidney disease. PLoS ONE, 8(2), Article numebere56096, 5 February 2013
 3. Adsf
 4. Asdf
 5. asd
18. Fekecs T, Kalmár-Nagy K, **Szakály P**, Németh K, Moezzi M, Zapf I, Horváth OP, Bartho-Szekeres J, Ferencz A: Changes of progesterone-induced blocking factor in patients after kidney transplantation. Transplantation Proceedings 43:(10), 3694-6, 2011
IF: 1,005
Független idéző: 2
1. Dsf
 2. Dsf
19. Fekecs T, Kádár Zs, Lengyel Zs, Battyáni Z, Kalmár nagy K, **Szakály P**, Wéber Gy, Horváth ÖP, Ferencz A: Szervtranszplantációt követő börgyógyászati szűrővizsgálat jelentősége a non-melanoma bőrtumorok diagnosztikája és kezelése céljából. Börgyógyászati és Venerológiai Szemle 87:(1), 9-14, 2011
20. Horvath G, Brubel R, Kovacs K, Reglodi D, Opper B, Ferencz A, **Szakaly P**, Laszlo E, Hau L, Kiss P, Tamas A, Racz B: Effects of PACAP on oxidative stress-induced cell death in primary rat kidney and human hepatocyte cell cultures. Journal of Molecular Neuroscience 43:(1), 67-75, 2011
IF: 2,504
Független idéző: 15
1. Pinhasov A, Neshar E, Gross M, Turgeman G, Kreinin A, Zadid G. The role of PACAP signaling system in depression. Curr Pharm Des 2011; 17: 990-1001
 2. Ji H, Zhang Y, Shen X, Gao F, Huang CY, Abad C, Busutti RW, Waschek JA, Kupiec-Weglinski JW. Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation via cAMP-PKA pathway. Hepatology March 2012; 57(3), 1225-37
 3. Vacas E, Bajo AM, Schally AV, Sanchez-Chapado M, Prieto JC, Carmena MJ. Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells. Peptides 2012; 38: 275-281.
 4. Vacas E, Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Schally AV, Prieto JC, Carmena MJ: Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation. Biochimica Et Biophysica Acta - Molecular Cell Research Volume: 1823 Issue: 10 Pages: 1676-1685 Published: Oct 2012
 5. Eiden LE: PACAP and cellular Protection: Cellular Protection by Members of the

VIP/Secretin Family with an Emphasis on Pituitary Adenylate Cyclase Activating Polypeptide (PACAP). In: *Neuropeptides in Neuroprotection and Neurogeneration*. ISBN: 978-1-4398-3062-8

6. Kambe Y, Miyata A: Role of mitochondrial activation in PACAP dependent neurite outgrowth. *Journal of Molecular Neuroscience*. Volume: 48, Issue: 3, Pages: 550-557, DOI: 10.1007/s12031-012-9754-0, Published: Nov 2012
 7. Wu L, Wang J, Chen X, Hong A: Expression, identification and biological effects of the novel recombination protein, PACAP38-NtA, with high bioactivity. *International Journal of Molecular Medicine* 2015; 35(2): 376-82
 8. Das
 9. Asd
 10. Asd
 11. Asd
 12. Asd
 13. Adf
 14. Df
 15. df
21. **Szakaly P**, Laszlo E, Kovacs K, Racz B, Horvath G, Ferencz A, Lubics A, Kiss P, Tamas A, Brubel R, Opper B, Baba A, Hashimoto H, Farkas J, Matkovits A, Magyarlaki T, Helyes Z, Reglodi D: Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo ischemia/reperfusion injury. *Neuropeptides*, 45:(2), 113-21, 2011

IF: 1,553

Független idéző: 14

1. Ji H, Zhang Y, Shen X, Gao F, Huang CY, Abad C, Busutti RW, Waschek JA, Kupiec-Weglinski JW. Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation via cAMP-PKA pathway. *Hepatology* March 2013; 57(3), 1225-37
2. Eiden LE: PACAP and cellular Protection: Cellular Protection by Members of the VIP/Secretin Family with an Emphasis on Pituitary Adenylate Cyclase Activating Polypeptide (PACAP). In: *Neuropeptides in Neuroprotection and Neurogeneration*. ISBN: 978-1-4398-3062-8
3. Vacas OE: Receptores Y vias de senalizacion de VIP como dias terapeuticas en el cancer renal. PhD disszertáció, 2012
4. Han PC, Tang ZW, Yin JX, Maalouf M, Beach TG, Reiman EM, Shi JO: Pitui adenylate cyclase-activating polypeptide protects against beta-amyloid toxicity. *Neurobiology of ageing* (ISSN: 0197-4580) 35: (9) pp. 2064-2071. (2014)
5. Qew
6. Qwe
7. Qwe
8. Qwe
9. Wer
10. We

11. Wer
12. Ew
13. Ewr
14. err

22. Ison MG, **Szakaly P**, Shapira MY, Kriván G, Nist A, Dutkowski R: Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipient. *Antiviral Therapy* 17:(6), 955-64, 2012

IF: 3,073

Független idéző: 23

1. Arslan D, Danzinger-Isakov L: Respiratory viral infections in pediatric solid organ and hamatopoietic stem cell transplantation. *Current Infectious Disease Repotrs* Volume: 14 Issue: 6 Pages: 658-667 Published: Dec 20122
2. Mossad SB, Yen-Lieberman B, Shrestha NK, Mossad DM, Mawhorter SD, Tage AJ, Tomford WJ, Johnson LT, Lard M, Fraser TG, Dhar S, Van Duin D, Shrestha RK, Rehm SJ, Avery RK, Gordon SM: Characteristics of transplant recipients who developed influenza in 2007-08 despite influenza vaccination. *Journal of Vaccines and Vaccination* 4:(3), S15-6, 2013
3. Shalhoub S, Husain S: Community-acquired respiratory viral infection in lung transplant recipients. *Current Opinion in Infectious Diseases* 26:(4), 302-8, 2013
4. Anonymous: Current World Literature. *Current Opinion In Organ Transplantation* (ISSN: 1087-2418) 18: (5) pp. 601-629. (2013)
5. Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman: European guidlines for prevention and management of influenza in hematopetic stem cell transplantation and leukemia patients: summary of ECIL-4(2011), on behalf of ECIL, a joint venture of EVMT, EORTC, ICHS and ELN. *Transplant Infectious Disease*, DOI: 10.1111/tid.12054, 31 JAN 2013
6. Labella AM, Merel SE: Influenza. *Medical Clinics of North America* 97:(4), 621-45, 2013
7. Marcos LA, Gotuzzo E: Intestinal protozoan infections in the immunocompromised host. *Current opinion in infectious diseases* 26:(4), 295-301, 2013
8. López-Medrano F, Cordero E, Gavaldá J, Cruzado JM, Marcos MÁ, Pérez-Romero P, Sabé N, Gómez-Bravo MÁ, Delgado JF, Cabral E, Carratalá J: Management of influenza infection in solid-organ transplant recipients: Consensus statement of the Gurop for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SIEMC) and the Spanish Network for Research in Infectious Diseases (REIPI). *Enfermedades Infecciosas y Microbiología Clínica* 31: (8) pp. 526.e1-526.e20. (2013)
9. Manuel O, Estabrook M: RNA respiratory viruses in solid organ transplantation. *American Journal of Transplantation*, 13(4), 212-219, March 2013
10. D
11. AD
12. AD

13. AD
14. FA
15. DSF
16. ASD
17. FADS
18. FA
19. SDF
20. ASDF
21. DSF
22. SDF
23. DSF

23. Reglodi D, Kiss P, Horvath G, Lubics A, Laszlo E, Tamas A, Racz B, **Szakaly P**: Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. *Neuropeptides* 46:(2), 61-70, 2012

IF: 2,067

Független idéző: 10

1. Kaiser EA, Russo Af: CGRP and migraine: Couls PACAP play a role too? *Neuropeptides* 47: (6)451-61, 2013
2. Vacas E, Muñoz-Moreno L, Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ: Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression *Int. J. Biochem. Cell Biol. (ISSN: 1878-5875)* 53: pp. 295-301. (2014)
3. ASD
4. AS
5. Das
6. Das
7. D
8. Asd
9. ASD
10. ASD

24. Reglodi D, Kiss P, Szabadfi K, Atlasz T, Gabriel R, Horvath G, **Szakaly P**, Sandor B, Lubics A, Laszlo E, Farkas J, Matkovits A, Brubel R, Hashimoto H, Ferencz A, Vincze A, Helyes Z, Welke L, Lakatos A, Tamas A.: PACAP is an Endogenous Protective Factor-Insights from PACAP-Deficient Mice. *Journal of Molecular Neuroscience* 48:(3), 482-92, 2012

IF: 2,891

Független idéző: 10

1. Yu R, Guo X, Huang L, Zeng Z, Zhang H. The novel peptide PACAP-TAT with enhanced traversing ability attenuates the severe lung injury induced by repeated smoke inhalation. *Peptides* 2012; 38: 142-149.
 2. Basille-Dugay M, Vaudry H, Fournier A, Gonzalez B, Vaudry D: Activation of PAC1 receptors in rat cerebellar granule cells stimulates both calcium mobilization from intracellular stores and calcium influx through N-type calcium channels. *Frontiers in endocrinology* 4:paper 56, 2013
 3. Watson MB, Nobuta H, Abad C, Lee SK, Bala N, Zhu C, Richter F, Chesselet M-F, Waschek JA: PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice. *Neuroscience* 240:277-86, 2013
 4. Ringer C, Büning LS, Schäfer MKH, Eiden LE, Weihe E, Schütz B: PACAP signaling exerts opposing effects on neuroprotection and neuroinflammation during disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. *Neurobiology of Disease*, 54, 39-42, June 2013
 5. Kormos V, Gaszner B: Role of neuropeptides in anxiety, stress and depression: From animals to humans. *Neuropeptides* 47: (6)401-19, 2013
 6. Miyamoto K, Tsumuraya T, Ohtaki H, Dohi K, Satih K, Xu ZF, Tanaka S, Murai N, Watanabe j, Sugiyama K, Aruga T, Shioda S: PACAP 38 suppresses cortical damage in mice with traumatic brain injury by enhancing antioxidant activity. *Journal of Molecular Neuroscience* 2014; 54(3): 370-9
 7. Kong Y, Zhang H, He X, Liu C, Piao L, Zhao G, Zhen Y: Endoscopic management for pancreatic injuries due to blunt abdominal trauma decreases failure of nonoperative management and incidence of pancreatic-related complications. *Injury* 45: (1)134-40, 2014
 8. Muller LPD, Sargoy A, Rodriguez AR, Brecha NC: Melanopsin Ganglion Cells Are the Most Resistant Retinal Ganglion Cell Type to Axonal Injury in the Rat Retina *PLOS ONE* (ISSN: 1932-6203) 9: (3) Paper e93274. (2014)
 9. Njaine B, Rocha-Martins M, Vieira-Vieira CH, De-Melo LDB, Linden R, Braas K, May V, Martins RAP, Silveira MS: Pleiotropic Functions of Pituitary Adenylyl Cyclase-Activating Polypeptide on Retinal Ontogenesis: Involvement of KLF4 in the Control of Progenitor Cell Proliferation. *J Mol Neurosci* (ISSN: 0895-8696) 2014: p. &. (2014)
 10. Cui Q, Ren C, Sollars PJ, Pickard GE, So KF: The injury resistant ability of melanopsin-expressing intrinsically photosensitive retinal ganglion cells. *Neuroscience* 2015; 284: 845-53
25. Kalmár Nagy K, Horváth S, **Szakály P**, Piros L, Langer R: Szimultán hasnyálmirigy-vese transzplantáció helye a diabetes mellitus kezelésében. *Orvosi Hetilap* 154:(22), 850-6, 2013
- Független idéző: 1
1. Szuromi: From the 4th interdisciplinary conference of orvosi hetilap: *Orvosi Hetilap* 154: (46) 1811-12, 2013
26. Sandor B, Varga A, Rabai M, Toth A, Papp J, Toth K, **Szakaly P**: Aspirin resistance as cardiovascular risk after kidney transplantation. *Korea-Australia Rheology Journal* 26:(2)

pp. 237-241. (2014)

IF: 0.632

27. Laszlo E, Kiss P, Horváth G, **Szakály P**, Tamás A, Reglődi D: The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion Acta Biologica Hungarica 65: (4)369-78 (2014)

IF: 0.563

Független idéző: 6

1. Dfad
2. Asdf
3. Asdf
4. Asdf
5. Sd
6. fsdf

28. Varga A, Sándor B, Kalmar-Nagy K, Tóth A, Viola M, Gombos K, Tóth K, **Szakály P**: Acetylsalicylic acid resistance after renal transplantation. In vivo 29: (1), 141-4 (2015)

IF: 1,148

29. Varga A, Sandor B, Nagy KK, Praksch D, Gombos K, Toth A, Toth K, **Szakaly P**: Clopidogrel resistance after renal transplantation. In Vivo. 2015 Mar-Apr;29(2):301-3.

IF: 1,148

Független idéző: 2

1. Dfad
2. Asdf

30. Laszlo E, Varga A, Kovacs K, Jancso G, Kiss P, Tamas A, **Szakaly P**, Fulop B, Reglodi D: Ischemia/reperfusion-induced Kidney Injury in Heterozygous PACAP-deficient Mice. Transplant Proc. 2015 Sep;47(7):2210-5. doi: 10.1016/j.transproceed.2015.07.027.

IF: 0,867

Független idéző: 2

1. Dfad
2. Asdf

31. Schwarcz A, **Szakály P**, Büki A, Dóczy T: Treatment of post-spondylodesis, adjacent-segment disease with minimally invasive, anterolateral surgery on the lumbar spine: is there is no need for dorsal operation? Ideggyogy Sz. 2015 Jul 30;68(7-8):273-7. Hungarian.

32. Praksch D, Sandor B, Nagy KK, Viola M, Toth A, Toth K, **Szakaly P**, Varga A: Acetylsalicylic Acid Resistance After Simultaneous Pancreas-Kidney Transplantation. Transplant Proc. 2016 Sep;48(7):2555-2557. doi: 10.1016/j.transproceed.2016.07.008.

IF: 0,908

33. Wagner L, Kalmár-Nagy K, Toronyi É, Török Sz, Patonai A, **Szakály P**: Experience with mycophenolate mofetil containing immunosuppressive regimen in de novo kidney transplant recipients (ORANGE study). *Hypertonia és Nephrologia* 2018;22(1):6-9.
34. **Szakály P**, Kalmar-Nagy K, Praksch D, Vas T, Varga A. More than Twenty Years' Experience with "Zero-Hour" Transplant Kidney Biopsy. *Clin Surg.* 2018; 3: 2153.
IF: 1,820
35. Laszlo E, Juhasz T, Varga A, Czibere B, Kovacs K, Degrell P, Horvath G, Jancso G, **Szakály P**, Tamas A, Reglodi D: Protective Effect of PACAP on Ischemia/Reperfusion-Induced Kidney Injury of Male and Female Rats: Gender Differences. *J Mol Neurosci.* 2018 Nov 16. doi: 10.1007/s12031-018-1207-y. [Epub ahead of print]
IF: 2,454
36. Wagner L, Wittmann I, Piros L, P Szabó R, **Szakály P**: Diabetology and solid organ transplantation. *Orv Hetil.* 2018 Nov;159(46):1930-1939. doi: 10.1556/650.2018.31281. Hungarian.